Moteur de recherche d’entreprises européennes
Financement de l’UE (6 700 000 €) : CARdiomyopathie dans le diabète de type 2 Hor01/03/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
CARdiomyopathie dans le diabète de type 2
A rapidly evolving epidemic in Type 2 Diabetes (T2DM) is afflicting all ages, sexes and socioeconomic classes which includes serious comorbidities such as heart diseases. While ischaemic heart disease represents the major cause of death of T2DM patients, heart failure (80% of Heart Failure with preserved Ejection Fraction) is the second most common cardiovascular disease in T2DM patients. The aim of CARDIATEAM is to determine whether T2DM represents a central mechanism contributing to the pathogenesis and progression of a specific cardiomyopathy, called “diabetic cardiomyopathy” (DCM), assessing whether DCM is unique and distinct from the other forms of heart failure. To achieve this aim CARDIATEAM will build up a deeply phenotyped cohort, including an innovative imaging protocol, based on privileged access within the CARDIATEAM to already existing highly pertinent cohorts of diabetes and heart failure patients and control groups. Central biobanking of the cohort samples will allow detailed omics analysis that will feed together with the phenotype and imaging data into the central CARDIATEAM database. The data gathered will enable unsupervised machine-learning for clustering this heterogeneous population on phenotypic differences beyond diabetes. State-of-the-art big-data processing techniques and disease modeling will allow for controlling for common confounders such as BMI, smoking, age and blood pressure and will finally lead to the identification of new imaging and molecular biomarkers as well as understanding the taxonomy of the development and progression of DCM. Tailored preclinical models will be developed to explore the identified pathways revealing new therapeutic targets. The results of CARDIATEAM will be able to impact clinical care with the stratification of patients into risk groups of developing DCM, earlier diagnosis of DCM and an improvement of therapy thanks to better assessment of underlying pathophysiology and identification of new biomarkers.
| Academisch Ziekenhuis Groningen | 0,00 € |
| Assistance Publique Hopitaux de Paris | 387 500 € |
| BAYER AG | 0,00 € |
| 0,00 € | |
| 0,00 € | |
| 655 500 € | |
| Eli Lilly and Company Ltd. | 0,00 € |
| Fundacio Hospital Universitari Vall D'Hebron - Institut de Recerca | 0,00 € |
| Fundacio de Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi i Sunyer | 0,00 € |
| Fundacion para La Investigacion Biomedica del Hospital Gregorio Maranon | 0,00 € |
| Fundacion para La Investigacion Biomedica del Hospital Universitario Ramon y Cajal | 0,00 € |
| HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM für GESUNDHEIT UND UMWELT GmbH | 269 526 € |
| Hospices Civils de Lyon | 202 709 € |
| Inserm Transfert SA | 310 250 € |
| Institut National de la Sante et de la Recherche Medicale | 1 053 229 € |
| 0,00 € | |
| Katholieke Universiteit Leuven | 94 783 € |
| Luxembourg Institute OF Health | 588 156 € |
| Metabrain Research | 28 150 € |
| Opale | 392 481 € |
| SIB SWISS INSTITUTE OF BIOINFORMATICS | 648 000 € |
| Sanofi-Aventis Recherche & Developpement | 0,00 € |
| Stichting Amsterdam UMC | 0,00 € |
| Stichting Netherlands Heart Institute | 464 374 € |
| The Queen's University of Belfast | 30 000 € |
| UNIVERSITAETSKLINIKUM AACHEN | 138 750 € |
| UNIVERSITATSKLINIKUM HEIDELBERG | 124 975 € |
| Universita Degli Studi DI Torino | 407 616 € |
| Universitair Medisch Centrum Utrecht | 0,00 € |
| Universite d'AIX Marseille | 213 375 € |
| Universiteit Maastricht | 140 625 € |
| University of Dundee | 550 000 € |
https://cordis.europa.eu/project/id/821508
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "Academisch Ziekenhuis Groningen - Financement de l’UE (6 700 000 €) : CARdiomyopathie dans le diabète de type 2"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
